NCT05988450进行中（未招募）不适用
A Prospective, Multicenter, Single Arm Clinical Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter in Patients With Moderate-severe or Severe Functional MR (FMR)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 125
- 试验地点
- 1
- 主要终点
- Rate of all-cause death and hospitalization for heart failure
研究概览
简要总结
To verify the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter produced by Shanghai Shenqi Medical Technology Co., Ltd. in patients with moderate-severe (3 +) or severe (4 +) functional MR (functional MR) who still have symptoms after full treatment.
详细描述
This study is a prospective, multi-center, single arm clinical study designed to evaluate the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter in patients with moderate-severe (3 +) or severe (4 +) functional MR (Functional MR) who still have symptoms after adequate treatment. This trial will be conducted at 41 sites in China and is planned to include a total of 118 subjects. All subjects received the trial device for transcatheter mitral valve clip delivery system and steerable guide catheter, and were followed up at 30 days, 6 months, and 12 months after surgery. The composite endpoint of all-cause death and hospitalization for heart failure was assessed at 12 months after surgery. After the 12th month follow-up, the statistical analysis, clinical summary and application for product registration were carried out.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe functional MR (FMR) ≥3+ as determined by transthoracic echocardiography (TTE);
- •Note: Eligible TTE must be obtained at least 30 days after the subject has been stabilized on optimal therapy (including Guideline Directed Medical Therapy GDMT). In the judgment of the center's cardiac team, subjects have received adequate treatment according to applicable criteria, including treatment for coronary artery disease, left ventricular dysfunction, MR, and heart failure (e.g., with cardiac resynchronization therapy (CRT or CRT-D), implantable cardioverter-defibrillator (ICD) implantation, coronary revascularization, and stable GDMT (see Appendix III for the definition of GDMT).
- •Age ≥ 18 years old, regardless of gender;
- •Cardiac function classification NYHA class II, III or ambulatory IV a;
- •At least one hospitalization for heart failure or subjects with high BNP > 150 pg/ml or high NT-proBNP > 600 pg/ml in the past 12 months.
- •Note: BNP or NT-proBNP must be obtained after the subject has stabilized on optimal therapy including Guideline Directed Medical Therapy (GDMT) at least 30 days. The patients can understand the purpose of the trial, voluntarily participate and sign an informed consent form, and are willing to undergo relevant tests and clinical follow-up.
- •Left ventricular end-systolic diameter (LVESD)≤70mm
- •The MR beam mainly originates from the A2/P2 area
- •Mitral valve coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets>10mm
- •Mitral valve effective orifice area (EOA) ≥ 4.0cm2
排除标准
- •History of mitral valve surgery;
- •Patients with infective endocarditis or suggestive of active infection;
- •Complicated with severe untreated coronary artery disease;
- •Patients with pulmonary hypertension (pulmonary systolic blood pressure>70mmHg);
- •patients with transthoracic echocardiographic evidence of moderate-severe to severe right ventricular dysfunction;
- •Left heart ejection fraction <20%;
- •Patients who are extremely frail and cannot tolerate general anesthesia surgery or is in the state of shock requiring circulatory support;
- •Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis;
- •Severe renal insufficiency (eGFR ≤ 25 mL/min) or requiring chronic renal replacement therapy;
- •Patients with definite coagulation disorders and severe coagulation system diseases;
- •Patients with clear contraindications to the use of anticoagulants;
- •Patients with stroke or transient cerebral ischemic attack within 30 days;
- •Received cardiac pacemaker therapy or cardiac resynchronization therapy (CRT, CRT-D) or implanted cardioverter-defibrillator (ICD) implantation therapy within 30 days;
- •Any intracardiac mass, left ventricular or atrial thrombus detected on transthoracic echocardiography;
- •Severe tricuspid TR;
- •Patients with other valve disease requiring surgery or interventional therapy;
- •Patients with severe macrovascular disease requiring surgical treatment;
- •Severe symptomatic carotid stenosis (>70% on ultrasonography) or carotid stenting within 30 days;
- •Patients with inappropriate anatomical structures of the heart and valves indicated by imaging examinations;
- •Known allergy to contrast agents and nickel-titanium memory alloy products;
- •<Resting systolic blood pressure 90 mmHg or >160 mmHg;
- •Patients with diseases that seriously affect the evaluation of treatment, such as patients with severe neurological lesions affecting cognitive ability, patients with malignant tumors, etc.;
- •Patient life expectancy < 12 months;
- •Patients with severe thoracic deformity;
- •Women who are pregnant, breastfeeding, or planning to become pregnant within the next 12 months.
结局指标
主要结局
Rate of all-cause death and hospitalization for heart failure
时间窗: 12 months
Freefrom of all-cause death and hospitalization for heart failure
次要结局
- Device success rate(30 days after surgery)
- Rate of hospitalization for heart failure at 30 days, 6 months, and 12 months after surgery;(30 days, 6 months, and 12 months after surgery)
- Technical success rate(Immediate postoperative)
- The rate of NYHA heart function class I or II at 30 days, 6 months, and 12 months after surgery;(30 days, 6 months, and 12 months after surgery)
- Improvement in quality of life from baseline at 12 months after surgery (as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) score);(12 months after surgery)
- Surgical success rate(30 days after surgery)
- Rate of MR 2+ or less than 2+ at 30 days, 6 months, and 12 months after surgery;(30 days, 6 months, and 12 months after surgery)
- Improvement in 6-minute walk distance from baseline at 12 months after surgery;(12 months after surgery)
- Improvement in left ventricular end-diastolic volume (LVEDV) from baseline at 12 months after surgery;(12 months after surgery)
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
不适用
Safety and Effectiveness Study of SQ-Kyrin TMVr System for Degenerated Mitral RegurgitationDegenerated Mitral RegurgitationNCT06467110Shanghai Shenqi Medical Technology Co., Ltd118
尚未招募
不适用
To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical TreatmentMitral Valve InsufficiencyNCT05508438Pan Xiangbin140
招募中
不适用
Transcatheter Mitral Valve InterventiOn Single Center Registry in CHinese Patients With Mitral Valve Disease (TORCH-M)Mitral Valve DiseaseNCT04954404Second Affiliated Hospital, School of Medicine, Zhejiang University2,000
招募中
不适用
To Evaluate Safety and Effectiveness of Transcatheter Aortic Valve System in Patients With Severe Aortic StenosisAortic Valve StenosisNCT04893603Chengdu Silara Meditech Inc.120
进行中（未招募）
不适用
ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic StenosisAortic Valve StenosisNCT03517436Edwards Lifesciences101